Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Levin

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Journal of Medicinal Chemistry|February 21, 2026
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised CancersJustin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, et al.
Journal of Medicinal Chemistry|August 14, 2025
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor ActivityAndrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, et al.
Gut|July 18, 2023
An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principlesRobert S Bresalier, Carlo Senore, Graeme P Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forwardGary J Kelloff, Scott M Lippman, Andrew J Dannenberg, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F ActivityShilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature|August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsShilpa Singh, Catherine E Gleason, Min Fang, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Journal of Medicinal Chemistry|February 21, 2026
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised CancersJustin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, et al.
Journal of Medicinal Chemistry|August 14, 2025
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor ActivityAndrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, et al.
Gut|July 18, 2023
An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principlesRobert S Bresalier, Carlo Senore, Graeme P Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forwardGary J Kelloff, Scott M Lippman, Andrew J Dannenberg, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F ActivityShilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature|August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsShilpa Singh, Catherine E Gleason, Min Fang, et al.
Pageof 8